Norbert VEY
MD
-
General Director at Institut Paoli Calmettes | Professor of Hematology at Aix-Marseille University
AMU, IPC
The new immunotherapy antibodies currently developed by biotech companies from Marseille reflect the teams' dynamism and the extraordinary local potential.
As a clinician involved for several years in cancer immunotherapy, in particular in leukemias, the creation of Marseille Immunopôle is a significant step forward. With the experience of the development of anti-KIR antibodies, we have shown the creatity and efficiency of the Marseille’s network in the field of immuno-oncology: from basic (CIML) to clinical research (IPC-SIRIC Marseille) through translational (CRCM) and industry research (Innate Pharma).
MI will enable the development of original and highly innovative approaches in immunotherapy, based on these three pillars. New molecules currently developed by biotech companies from Marseille reflect the teams’ dynamism and the extraordinary local potential.
#clinique #rechercheHave a look on our testimonies
Each year, a large number of clinical trials are conducted by APHM clinicians alone or in partnership with industry players in biopharmaceuticals.
Frédéric VELY
AMU, AP-HM, CIML
“Our immunotherapy antibodies are positioned at the crossroads of two immunology fields with high potential: the γ9δ2 T cells and a novel superfamily of immunomodulators, butyrophilins”
Pierre d’EPENOUX
Imcheck Therapeutics
Our aim is simple: to position ourselves upstream of the diagnosis and to propose innovative treatments to patients
Emmanuelle CHARAFE-JAUFFRET
AMU, IPC, CRCM
This is the DNA of the cluster to feed local excellence, including, of course, fundamental and applied immunology, and to support the emergence of sector initiatives with strong potential.
Émilie ROYERE
Eurobiomed
your commitment to MI